Unique volatolomic signatures of TP53 and KRAS in lung cells

por Davies, M P A, Barash, O, Jeries, R, Peled, N, Ilouze, M, Hyde, R, Marcus, M W, Field, J K, Haick, H
Publicado 2014

1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 rando...

por Giaccone, G., Felip, E., Cobo, M., Campelo, R. Garcia, DENIS, F., Quoix, E., Madroszyk, A., Debieuvre, D., Hilgers, W., Moran, T., Galetta, D., Romano, G.D., Cappuzzo, F., Robinet, G., Masson, P., Viteri, S., Peled, N., Costantini, D., Dziadziuszko, R., Besse, B.
Publicado 2020

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

por Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.
Publicado 2019